Abstract
The lipolysis-stimulated lipoprotein receptor (LSR) displays an important regulatory role in cancer. However, the association between LSR and lung cancer is still elusive. Here, the candidate oncogene LSR on Ch.9q was obtained and assessed by bioinformatics analysis of The Cancer Genome Atlas (TCGA) dataset of lung cancer. We conducted clinical pathology and survival analysis based on the lung cancer database. We assessed the biological effects of LSR in lung cancer cells on cell proliferation. Our data indicated that LSR was upregulated in lung cancer cells. Meanwhile, LSR was identified in this study to be a poor prognostic factor, and its high expression exhibited relations with grades, stages, and nodal metastasis status. Using in vitro analysis, our data revealed that LSR could promote lung cancer progression by regulating cell proliferation, migration, and invasion. In our study, our data demonstrated that LSR was a tumor promoter for lung cancer and was a potential biomarker and target for lung cancer prognosis and treatment.
Highlights
Lung cancer is becoming the pivotal inducer of male and female mortality worldwide
Through the bioinformatics analysis of The Cancer Genome Atlas (TCGA) dataset, we found that LSR might be a potential oncogene of lung cancer
Given TCGA dataset, we found that LSR expression in lung cancer tissues was greatly higher than that in normal lung tissues (Figure 1(a))
Summary
Lung cancer is becoming the pivotal inducer of male and female mortality worldwide. The poor prognosis may be due to the high proportion of advanced patients and the lack of active anticancer treatment for most early patients [2]. The probable reason for the high mortality of lung cancer is caused by genetic and environmental factors and tumor treatment [3]. The therapeutic efficacy of patients with lung cancer has been dramatically ameliorated after combined use of surgery, radiotherapy, and systemic therapy on patients with early disease [4]. With the in-depth research on the molecular mechanism of lung cancer, the introduction of targeted therapies, immune methods, and chemotherapy in the treatment process has greatly improved the treatment methods for patients with advanced lung cancer [5]. It is still necessary to further explore reliable lung cancer phenotype markers to improve the effect of lung cancer treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
